All Stories

  1. Correction: Lopez-Gordo et al. Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights. Viruses 2024, 16, 442

    Article • Viruses, August 2024, MDPI AG

    Head of Viral Platforms Thomas Weber

  2. Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights

    Article • Viruses, March 2024, MDPI AG

    Head of Viral Platforms Thomas Weber

  3. Selective Anti-AAV Antibody Depletion by Hemapheresis and Immunoadsorption

    Article • January 2022, Springer Science + Business Media

    Head of Viral Platforms Thomas Weber

  4. Hydroxylation of N-acetylneuraminic Acid Influences the in vivo Tropism of N-linked Sialic Acid-Binding Adeno-Associated Viruses AAV1, AAV5, and AAV6

    Article • Frontiers in Medicine, December 2021, Frontiers

    Head of Viral Platforms Thomas Weber

  5. Correction: Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

    Article • Gene Therapy, March 2021, Springer Science + Business Media

    Head of Viral Platforms Thomas Weber

  6. Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions

    Article • Frontiers in Immunology, March 2021, Frontiers

    Head of Viral Platforms Thomas Weber

  7. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

    Article • Gene Therapy, March 2021, Springer Science + Business Media

    Head of Viral Platforms Thomas Weber

  8. Identification of Genes and Pathways Regulated by Lamin A in Heart

    Article • Journal of the American Heart Association, August 2020, Wolters Kluwer Health

    Head of Viral Platforms Thomas Weber

  9. Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption

    Article • Molecular Therapy — Methods & Clinical Development, March 2020, Elsevier

    Head of Viral Platforms Thomas Weber

  10. Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer

    Article • Journal of Cardiovascular Development and Disease, February 2019, MDPI AG

    Head of Viral Platforms Thomas Weber

  11. AAV Vectors for Efficient Gene Delivery to Rodent Hearts

    Article • January 2019, Springer Science + Business Media

    Head of Viral Platforms Thomas Weber

  12. Human Cardiac Gene Therapy

    Article • Circulation Research, August 2018, Wolters Kluwer Health

    Head of Viral Platforms Thomas Weber

  13. A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity

    Article • Human Gene Therapy, August 2018, Mary Ann Liebert Inc

    Head of Viral Platforms Thomas Weber

  14. Protein S Protects against Podocyte Injury in Diabetic Nephropathy

    Article • Journal of the American Society of Nephrology, March 2018, American Society of Nephrology

    Head of Viral Platforms Thomas Weber

  15. Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure

    Article • Journal of the American College of Cardiology, October 2017, Elsevier

    Head of Viral Platforms Thomas Weber

  16. Use of Adeno-Associated Virus Vector for Cardiac Gene Delivery in Large-Animal Surgical Models of Heart Failure

    Article • Human Gene Therapy Clinical Development, July 2017, Mary Ann Liebert Inc

    Head of Viral Platforms Thomas Weber

  17. Cardiac gene therapy with adeno-associated virus-based vectors

    Article • Current Opinion in Cardiology, May 2017, Wolters Kluwer Health

    Head of Viral Platforms Thomas Weber

  18. Do we need marker gene studies in humans to improve clinical AAV gene therapy?

    Article • Gene Therapy, January 2017, Nature

    Head of Viral Platforms Thomas Weber

  19. Production and Characterization of Vectors Based on the Cardiotropic AAV Serotype 9

    Article • December 2016, Springer Science + Business Media

    Head of Viral Platforms Thomas Weber

  20. Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids

    Article • Human Gene Therapy Methods, February 2016, Mary Ann Liebert Inc

    Head of Viral Platforms Thomas Weber

  21. High Capsid–Genome Correlation Facilitates Creation of AAV Libraries for Directed Evolution

    Article • Molecular Therapy, April 2015, Elsevier

    Head of Viral Platforms Thomas Weber

  22. Effectiveness of gene delivery systems for pluripotent and differentiated cells

    Article • Molecular Therapy — Methods & Clinical Development, January 2015, Elsevier

    Head of Viral Platforms Thomas Weber

  23. Cardiac I-1c Overexpression With Reengineered AAV Improves Cardiac Function in Swine Ischemic Heart Failure

    Article • Molecular Therapy, December 2014, Elsevier

    Head of Viral Platforms Thomas Weber

  24. Syntaxin 5-Dependent Retrograde Transport to thetrans-Golgi Network Is Required for Adeno-Associated Virus Transduction

    Article • Journal of Virology, November 2014, ASM Journals

    Head of Viral Platforms Thomas Weber

  25. Alternatively Spliced Tissue Factor Promotes Plaque Angiogenesis Through the Activation of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor SignalingCLINICAL PERSPECTIVE

    Article • Circulation, August 2014, Wolters Kluwer Health

    Head of Viral Platforms Thomas Weber

  26. Gene Therapy: Charting a Future Course—Summary of a National Institutes of Health Workshop, April 12, 2013

    Article • Human Gene Therapy, June 2014, Mary Ann Liebert Inc

    Dr Satiro N De Oliveira, Head of Viral Platforms Thomas Weber

  27. Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure

    Article • Gene Therapy, February 2014, Nature

    Head of Viral Platforms Thomas Weber

  28. Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy

    Article • Human Gene Therapy Methods, April 2013, Mary Ann Liebert Inc

    Head of Viral Platforms Thomas Weber

  29. Response to ‘Run for your life … at a comfortable speed and not too far’

    Article • Heart, March 2013, BMJ

    Head of Viral Platforms Thomas Weber

  30. Quantification of AAV Particle Titers by Infrared Fluorescence Scanning of Coomassie-Stained Sodium Dodecyl Sulfate–Polyacrylamide Gels

    Article • Human Gene Therapy Methods, June 2012, Mary Ann Liebert Inc

    Head of Viral Platforms Thomas Weber

  31. Concomitant Intravenous Nitroglycerin With Intracoronary Delivery of AAV1.SERCA2a Enhances Gene Transfer in Porcine Hearts

    Article • Molecular Therapy, March 2012, Elsevier

    Head of Viral Platforms Thomas Weber

  32. Gene Therapy for Heart Failure

    Article • Circulation Research, March 2012, Wolters Kluwer Health

    Head of Viral Platforms Thomas Weber

  33. Intracellular transport of recombinant adeno-associated virus vectors

    Article • Gene Therapy, February 2012, Nature

    Head of Viral Platforms Thomas Weber

  34. Novel Approaches to Deliver Molecular Therapeutics in Cardiac Disease Using Adeno-Associated Virus Vectors

    Article • January 2012, Springer Science + Business Media

    Head of Viral Platforms Thomas Weber

  35. Neutralizing Antibodies Against AAV Serotypes 1, 2, 6, and 9 in Sera of Commonly Used Animal Models

    Article • Molecular Therapy, January 2012, Elsevier

    Head of Viral Platforms Thomas Weber

  36. Adeno-Associated Virus 2 Infection Requires Endocytosis through the CLIC/GEEC Pathway

    Article • Cell Host & Microbe, December 2011, Elsevier

    Head of Viral Platforms Thomas Weber

  37. Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors

    Article • Gene Therapy, March 2010, Nature

    Head of Viral Platforms Thomas Weber

  38. Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction

    Article • Virology, October 2007, Elsevier

    Head of Viral Platforms Thomas Weber

  39. pH-Dependent Lytic Peptides Discovered by Phage Display†

    Article • Biochemistry, May 2006, American Chemical Society (ACS)

    Head of Viral Platforms Thomas Weber

  40. Altering AAV tropism with mosaic viral capsids

    Article • Molecular Therapy, June 2005, Elsevier

    Head of Viral Platforms Thomas Weber

  41. Reconstitution of Ca2+-Regulated Membrane Fusion by Synaptotagmin and SNAREs

    Article • Science, April 2004, American Association for the Advancement of Science

    Head of Viral Platforms Thomas Weber

  42. Mutations in Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase Causing Increased Receptor Binding Activity and Resistance to the Transition State Sialic Acid Analog 4-GU-DANA (Zanamivir)

    Article • Journal of Virology, January 2003, ASM Journals

    Head of Viral Platforms Thomas Weber

  43. Liposome Fusion Assay to Monitor Intracellular Membrane Fusion Machines

    Article • January 2003, Elsevier

    Head of Viral Platforms Thomas Weber

  44. A putative link between exocytosis and tumor development

    Article • Cancer Cell, December 2002, Elsevier

    Head of Viral Platforms Thomas Weber

  45. Regulation of membrane fusion by the membrane-proximal coil of the t-SNARE during zippering of SNAREpins

    Article • Journal of Cell Biology, September 2002, Rockefeller University Press

    Head of Viral Platforms Thomas Weber

  46. Identification of synapsin I peptides that insert into lipid membranes

    Article • Biochemical Journal, February 2001, Portland Press Ltd.

    Head of Viral Platforms Thomas Weber

  47. Functional architecture of an intracellular membrane t-SNARE

    Article • Nature, September 2000, Nature

    Head of Viral Platforms Thomas Weber

  48. Close Is Not Enough

    Article • Journal of Cell Biology, July 2000, Rockefeller University Press

    Head of Viral Platforms Thomas Weber

  49. Snarepins Are Functionally Resistant to Disruption by Nsf and αSNAP

    Article • Journal of Cell Biology, May 2000, Rockefeller University Press

    Head of Viral Platforms Thomas Weber

  50. Putative fusogenic activity of NSF is restricted to a lipid mixture whose coalescence is also triggered by other factors

    Article • The EMBO Journal, March 2000, Wiley

    Head of Viral Platforms Thomas Weber

  51. Cathepsin D targeted by acid sphingomyelinase-derived ceramide

    Article • The EMBO Journal, January 2000, Wiley

    Head of Viral Platforms Thomas Weber

  52. Use of Affinity Chromatography and TID-Ceramide Photoaffinity Labeling for Detection of Ceramide-Binding Proteins

    Article • January 2000, Elsevier

    Head of Viral Platforms Thomas Weber

  53. Content mixing and membrane integrity during membrane fusion driven by pairing of isolated v-SNAREs and t-SNAREs

    Article • Proceedings of the National Academy of Sciences, October 1999, Proceedings of the National Academy of Sciences

    Head of Viral Platforms Thomas Weber

  54. Rapid and efficient fusion of phospholipid vesicles by the α-helical core of a SNARE complex in the absence of an N-terminal regulatory domain

    Article • Proceedings of the National Academy of Sciences, October 1999, Proceedings of the National Academy of Sciences

    Head of Viral Platforms Thomas Weber

  55. Cathepsin D targeted by acid sphingomyelinase-derived ceramide

    Article • The EMBO Journal, October 1999, Wiley

    Head of Viral Platforms Thomas Weber

  56. The Length of the Flexible SNAREpin Juxtamembrane Region Is a Critical Determinant of SNARE-Dependent Fusion

    Article • Molecular Cell, September 1999, Elsevier

    Head of Viral Platforms Thomas Weber

  57. Identification of intracellular ceramide target proteins by affinity chromatography and TID-ceramide photoaffinity labelling

    Article • Biochemical Society Transactions, August 1999, Portland Press Ltd.

    Head of Viral Platforms Thomas Weber

  58. SNAREpins: Minimal Machinery for Membrane Fusion

    Article • Cell, March 1998, Elsevier

    Head of Viral Platforms Thomas Weber

  59. Gene Therapy for Cardiovascular Diseases

    Article • Annals of Medicine, January 1996, Taylor & Francis

    Dr Seppo Yla-Herttuala, Head of Viral Platforms Thomas Weber

  60. The Myristoyl Moiety of Myristoylated Alanine-rich C Kinase Substrate (MARCKS) and MARCKS-related Protein Is Embedded in the Membrane

    Article • Journal of Biological Chemistry, August 1995, American Society for Biochemistry & Molecular Biology (ASBMB)

    Head of Viral Platforms Thomas Weber

  61. 2-(Tributylstannyl)-4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzyl Alcohol: A Building Block for Photolabeling and Crosslinking Reagents of Very High Specific Radioactivity

    Article • Journal of the American Chemical Society, March 1995, American Chemical Society (ACS)

    Head of Viral Platforms Thomas Weber

  62. Interaction of MARCKS, a major protein kinase C substrate, with the membrane

    Article • January 1995, Springer Science + Business Media

    Head of Viral Platforms Thomas Weber

  63. Insertion of Filamin into Lipid Membranes Examined by Calorimetry, the Film Balance Technique, and Lipid Photolabeling

    Article • Biochemistry, October 1994, American Chemical Society (ACS)

    Head of Viral Platforms Thomas Weber

  64. Identification of Functional Domains in the Cytoskeletal Protein Talin

    Article • European Journal of Biochemistry, September 1994, Wiley

    Head of Viral Platforms Thomas Weber

  65. Evidence for H(+)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane

    Article • Journal of Biological Chemistry, July 1994, Elsevier

    Head of Viral Platforms Thomas Weber

  66. Ceramide as an Activator Lipid of Cathepsin D

    Article • Springer Science + Business Media

    Head of Viral Platforms Thomas Weber